Gunderson Dettmer represented client Tarsus Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company, in its strategic partnership with LianBio to develop and commercialize its investigational therapeutic for eye conditions, TP-03, in Greater China.

In the announcement of the transaction, CEO of Tarsus Bobak Azamian, MD, PhD, said,  “We are thrilled to partner with LianBio to expand access to TP-03 in China, enabling us to advance our mission of revolutionizing treatments for patients in need, starting with eye care. With an exceptionally seasoned team and growing pipeline, we believe LianBio is well positioned to successfully commercialize TP-03 in Greater China. We look forward to expanding our global footprint in the second largest healthcare market in the world to deliver a much-needed treatment for patients with Demodex blepharitis and Meibomian Gland Disease.”

The Gunderson deal team was led by Brendan McCarthy and included Shu Hu.